| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.140 | 36.927 | 11.064 | 111.290 | 60.631 | 92.201 | 115.720 | 58.339 | 60.060 | 124.335 |
| Total Income - EUR | 3.167 | 36.987 | 11.415 | 113.055 | 61.164 | 94.804 | 116.000 | 58.920 | 60.234 | 125.424 |
| Total Expenses - EUR | 1.555 | 7.726 | 7.880 | 23.576 | 66.930 | 83.012 | 81.219 | 79.480 | 56.300 | 81.158 |
| Gross Profit/Loss - EUR | 1.612 | 29.262 | 3.534 | 89.479 | -5.766 | 11.792 | 34.781 | -20.560 | 3.934 | 44.266 |
| Net Profit/Loss - EUR | 1.517 | 28.154 | 3.268 | 88.349 | -6.374 | 10.926 | 33.647 | -21.144 | 3.333 | 41.418 |
| Employees | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 1 | 1 | 1 |
Check the financial reports for the company - G.v.f. Pharmaceutical Technologies Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 5.160 | 4.015 | 63.304 | 47.832 | 33.390 | 17.944 | 2.431 | 3.535 | 42.091 |
| Current Assets | 3.185 | 23.595 | 6.654 | 30.402 | 40.065 | 44.929 | 60.788 | 50.558 | 45.909 | 50.906 |
| Inventories | 0 | 0 | 0 | 0 | 1.929 | 0 | 0 | 0 | 67 | 0 |
| Receivables | 12 | 1.707 | 2.592 | 8.411 | 12.945 | 20.533 | 40.519 | 26.538 | 35.256 | 33.642 |
| Cash | 3.174 | 21.889 | 4.062 | 21.991 | 25.192 | 24.395 | 20.269 | 24.020 | 10.585 | 17.264 |
| Shareholders Funds | 1.562 | 28.199 | 3.311 | 91.600 | 83.452 | 71.739 | 72.272 | -21.103 | -17.706 | 23.811 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.623 | 557 | 7.358 | 2.107 | 4.445 | 6.579 | 6.459 | 74.092 | 67.149 | 69.186 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4614 - 4614" | |||||||||
| CAEN Financial Year |
4614
|
|||||||||
Comments - G.v.f. Pharmaceutical Technologies Srl